Abstract
CINCA syndrome (chronic, infantile, neurological , cutaneous, articular syndrome) also known as neonatal-onset multisystem inflammatory disease (NOMID) represents the most severe form of cryopyrin-associated periodic syndrome ( CAPS). This condition was found to be associated with missense mutations in the CIAS1/NALP3/PYPAF gene, which encodes cryopyrin. Cryopyrin is a member of the cytoplasmatic protein family CATERPILLER, which is involved in inflammasome molecular platform assembly, leading to inflammatory immune response and apoptosis regulation. It has been hypothesized that mutant cryopirin spontaneously oligomerizes and induces the inflammasome activation with elevated IL-1β production and autoinflammatory phenotype. Causative CIAS1 mutations have been detected in only half of the patients with CINCA and the genetic cause of the disease in patients who tested negative remains unclear.
Highlights
CINCA syndrome known as neonatal-onset multisystem inflammatory disease (NOMID) represents the most severe form of cryopyrin-associated periodic syndrome ( CAPS)
We describe two patients with severe CINCA syndrome who exhibited somatic CIAS1 mutations, with different percentage of mosaicism
Conventional mutation analysis of all exons of CIAS1 filed to evidence any mutation in the two patients
Summary
CINCA syndrome (chronic, infantile, neurological, cutaneous, articular syndrome) known as neonatal-onset multisystem inflammatory disease (NOMID) represents the most severe form of cryopyrin-associated periodic syndrome ( CAPS). This condition was found to be associated with missense mutations in the CIAS1/NALP3/ PYPAF gene, which encodes cryopyrin. Cryopyrin is a member of the cytoplasmatic protein family CATERPILLER, which is involved in inflammasome molecular platform assembly, leading to inflammatory immune response and apoptosis regulation. Causative CIAS1 mutations have been detected in only half of the patients with CINCA and the genetic cause of the disease in patients who tested negative remains unclear
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have